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Abstract
Introduction: Despite the extensive mechanistic and pathological characterization of the amyloid precursor protein
(APP)/presenilin-1 (PS-1) knock-in mouse model of Alzheimer’s disease (AD), very little is known about the AD-
relevant behavioral deficits in this model. Characterization of the baseline behavioral performance in a variety of
functional tasks and identification of the temporal onset of behavioral impairments are important to provide a
foundation for future preclinical testing of AD therapeutics. Here we perform a comprehensive behavioral
characterization of this model, discuss how the observed behavior correlates with the mechanistic and pathological
observations of others, and compare this model with other commonly used AD mouse models.
Methods: Four different groups of mice ranging across the lifespan of this model (test groups: 7, 11, 15, and
24 months old) were run in a behavioral test battery consisting of tasks to assess motor function (grip strength,
rotor rod, beam walk, open field ambulatory movement), anxiety-related behavior (open field time spent in
peripheral zone vs. center zone, elevated plus maze), and cognitive function (novel object recognition, radial arm
water maze).
Results: There were no differences in motor function or anxiety-related behavior between APP/PS-1 knock-in mice
and wild-type counterpart mice for any age group. Cognitive deficits in both recognition memory (novel object
recognition) and spatial reference memory (radial arm water maze) became apparent for the knock-in animals as
the disease progressed.
Conclusion: This is the first reported comprehensive behavioral analysis of the APP/PS1 knock-in mouse model of
AD. The lack of motor/coordination deficits or abnormal anxiety levels, coupled with the age/disease-related
cognitive decline and high physiological relevance of this model, make it well suited for utilization in preclinical
testing of AD-relevant therapeutics.
Keywords: Alzheimer’s disease, amyloid precursor protein/presenilin-1, motor behavior, anxiety behavior, cognition,
learning and memory, spatial reference memory, recognition memory, transgenic mouse model
Introduction
A large number of mouse models have been genetically
engineered in attempts to model different aspects of the
etiology and pathology of Alzheimer’s disease (AD).
While all transgenic mouse models generated to date
fail to replicate completely the pathology observed in
human AD, they have offered valuable insight into the
molecular mechanisms of AD and have provided a use-
ful preclinical platform with which to test potential AD
therapeutics [1]. Many of the currently used AD mouse
models are generated by random exogenous insertion of
genetic material into the host genome to produce over-
expression of a particular protein of interest. While this
approach is relatively straightforward and provides a
convenient way to examine a gene/protein of interest,
ectopic overexpression of a gene can lead to off-target
complications unrelated to the disease process that can
complicate experiments aimed at evaluating novel AD
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therapeutics. For example, ectopic overexpression of
even a wild-type (WT) transgene can evoke cellular,
anatomical, and behavioral abnormalities [2-7]. One way
to bypass these off-target complications common to
transgenic mice is to knock-in (KI) the gene of interest
into a specific genetic locus in the mouse genome.
The APPNLh/NLh × PS1P264L/P264L double gene-targeted
knock-in (APP/PS1 KI) mouse takes advantage of this
KI gene-targeted insertion with selective point muta-
tions in amyloid precursor protein (APP) and presenilin-
1 (PS-1) genes linked to familial AD pathology [3,8-11].
In general, the use of the genetic KI strategy potentially
increases the fidelity of a model system of a relevant dis-
ease process. A case in point is the APP/PS1 KI mouse,
which replicates much of the amyloid-dependent pathol-
ogies seen clinically in AD. For example, nearly identical
profiles of amyloid processing exist between observed
AD patients and these APP/PS1 KI mice [12]. Further,
these mice exhibit progressive amyloid deposition start-
ing at 6 months of age that increases linearly over time,
so that by 18 months of age they show many dense
amyloid deposits in regions such as the hippocampus
and dentate gyrus [11-14]. These amyloid depositions
consist of both neuritic and non-neuritic plaques with
high similarities to those seen in human AD [12]. Other
observed pathological changes for this model that are
relevant to the pathogenesis of AD include: increased
oxidative stress and metabolic disturbances starting as
early as 1 to 2 months of age, reduction of neuronal
L-type calcium channel activity in 14-month-old mice,
impaired hippocampal LTP, and age-related increases in
reactive gliosis and proinflammatory cytokine produc-
tion [11-13,15-17].
Despite the extensive biochemical and mechanistic
characterization of this APP/PS1 KI mouse model, less
is known about AD-relevant behavioral/cognitive deficits
of this model. One report describes cognitive deficits in
14-month-old APP/PS1 KI mice in a one-way active
avoidance task [16]. Another study showed an age-
dependent cognitive impairment in a Stone T-maze task
[18]. However, to date a comprehensive behavioral ana-
lysis of this AD model has not been reported. Little is
therefore known about the baseline behavioral profile
and the temporal onset of behavioral impairments in
this APP/PS1 KI model in a series of standard beha-
vioral tasks. Here we seek to fill this void in knowledge
by examining the cognition/behavioral profile (motor
behavior, anxiety-related behavior, and cognitive func-
tion) across the lifespan of the APP/PS1 KI mouse using
a cross-sectional design (age groups of 7, 11, 15, and
24 months old). We report here that the APP/PS1 KI
mouse shows no motor deficits or abnormal anxiety
levels at any of the ages tested. In addition, the APP/
PS1 KI mouse shows an age-dependent development of
cognitive deficits in two different memory domains rele-




Four different age groups (7, 11, 15, and 24 months) of
APPNLh/NLh × PS1P264L/P264L mice were used in this
study. This mouse model was originally developed at
Cephalon [11] using gene-targeted KI technology to
introduce the Swedish FAD K670N/M671L point muta-
tions, humanize the mouse b-amyloid sequence (NLh),
and introduce a proline to leucine (P264L) mutation in
the mouse PS-1 gene [8,9]. A useful characteristic of
this model is that because an endogenous promoter
drives the expression of each gene, development of AD-
like pathology occurs in the absence of APP or PS1
overexpression. Mice were maintained on a CD-1/129
background, and WT mice were obtained from hetero-
zygous APP-PS1 mating pairs and maintained as a sepa-
rate line for more than 20 generations of inbreeding, for
use as controls. All mice were genotyped by PCR analy-
sis of tail-snip DNA to monitor for the maintenance of
the appropriate genotype [22].
Animal protocols followed the principles and practices
outlined in the Guide for the Care and Use of Labora-
tory Animals, and were approved by the Institutional
Animal Care and Use Committee of the University of
Kentucky. All behavioral testing was performed in the
University of Kentucky Rodent Behavior Core. There
were no observable differences in mortality rates
between genotypes in this study, and behavioral data for
both genders were combined after observing no differ-
ences between the behavioral responses of male and
female mice for any age group tested.
Grip strength
Forelimb grip strength was measured in grams of resis-
tance using a digital force-gauging apparatus (Animal
Grip Strength System; San Diego Instruments, San
Diego, CA, USA). Forelimb strength was measured by
holding the mouse by the nape of the neck and by the
base of the tail. The forelimbs were placed on the ten-
sion bar pad, and the mouse was pulled back gently
until it could no longer grip the bar and was forced to
release its hold on the grip pad. The resistance was
automatically calculated in real time with the digital
force-gauging apparatus and the maximal resistance
achieved by each mouse was reported as the final grip
strength.
Rotor rod
The mice were placed on a rotating rod (3.18 cm dia-
meter) in lanes 11.5 cm wide to maintain the animal in
Webster et al. Alzheimer’s Research & Therapy 2013, 5:28
http://alzres.com/content/5/3/28
Page 2 of 15
the same direction while the bar is rotating (ROTOR-
ROD™ System; San Diego Instruments). The bar is
46 cm from the floor of the apparatus and the bar’s
speed of rotation was gradually and linearly increased
from 0 to 40 rpm across the 5-minute trial. Both the
latencies (seconds) and the distance (cm) at which the
mice were able to maintain their balance on the bar
were then recorded automatically using beam break
technology.
Beam walk
The beam walk protocol used in this study has pre-
viously been described [23]. Briefly, mice were trained
to walk along an 80 cm long and 3 cm wide beam ele-
vated 30 cm above the bench by metal supports to
reach an enclosed goal box. Mice were placed on the
beam at one end and allowed to traverse the beam to
reach the goal box. This was repeated using decreasing
size (3 cm, 2 cm, and 1 cm) beams. Foot slips were
scored when one or both hind limbs slipped from the
beam.
Open field activity
Mice were placed in a multi-unit open field maze (San
Diego Instruments) with field chamber (50 cm long ×
50 cm wide), and activity was recorded using EthoVision
XT 8.0 video tracking software (Noldus Information
Technology, Leesburg, VA, USA). Each 50 cm × 50 cm
unit was digitally divided into 25 quadrants of equal size
(nine central and 16 peripheral) using EthoVision XT
8.0 video tracking software. The nine central quadrants
are collectively referred to as the center zone and the 16
peripheral quadrants are collectively referred to as the
peripheral zone as previously described [24]. Data were
collected continually for 30 minutes and the distance
traveled (cm), velocity (cm/second), and time spent in
the center zone versus the peripheral zone were all
recorded and scored automatically. The open field task
is a popular model for assessing ambulatory movement
and anxiety-like behaviors in response to a novel envir-
onment. Distance traveled and movement speeds are
measures of ambulatory movement, whereas the amount
of time spent in the center zone versus the peripheral
zone is a measure of anxiety levels due to the rodent’s
natural thigmotaxis behavior when frightened [25].
Elevated plus maze
An elevated plus maze (San Diego Instruments) was
used to assess anxiety-related behavior in response to a
potentially dangerous environment. The elevated plus
maze consists of four arms (two enclosed arms and two
open arms) elevated 100 cm above the floor. Anxiety-
related behavior was defined as the degree to which the
subject avoided the open arms (perceived unsafe arms)
of the maze, preferring the closed arms (perceived safe
arm) of the maze. Each mouse was placed in the center
of the maze and the amount of time spent in each arm
was recorded automatically by EthoVision XT 8.0 video
tracking software (Noldus Information Technology).
Radial arm water maze
The radial arm water maze (RAWM) task can be used
to measure both spatial working memory [26,27] and
spatial reference memory. The maze procedure used in
this study was designed as a rapid measure of spatial
reference memory and has been previously described in
detail [28]. Briefly, the maze consisted of six arms 160 cm
in diameter with arm length 30 cm and common circular
swim area of 40 cm. The pool was filled with water until
the level was approximately 2 cm above (covering) a clear
(invisible) 10-cm circular platform. The platform was
placed in the back of an arm approximately 7 cm away
from the side and back walls. The pool was located in
the center of a room and enclosed by a black curtain.
Geometric extra-maze visual cues were fixed throughout
the study on three sides of the curtains.
The RAWM protocol consisted of a 2-day testing para-
digm. A staggered training schedule was used, running
the mice in cohorts of five or six mice, while alternating
the different cohorts through the trials over day 1 and
day 2 of the test. This alternating protocol was used to
avoid the learning limitations imposed by massed subse-
quent trials and to avoid fatigue that may result from
consecutive trials. During block 1 (six trials) and block 2
(six trials), mice were trained to identify the platform
location by alternating between a visible and a hidden
platform in the goal arm, with three hidden platform
trials and three visible platforms. Block 3 consisted of
three trials all with a hidden platform. For day 2, mice
were tested in three blocks of five trials each (15 total
trials), with only the hidden escape platform employed,
forcing the mice to use a spatial strategy to identify the
goal arm location.
Data are presented as the average errors per block, simi-
lar to the methods described in [28], and only errors dur-
ing the hidden platform trials are included in the analysis,
as they represent the spatial memory component of the
RAWM task. Errors were scored each time the subject
entered the arm not containing the platform. An arm
entry was defined as the mouse’s whole body moving past
the threshold of the entrance to an arm. After reaching
the platform, the mouse was allowed to remain on it for
10 seconds and was then removed, dried, and placed in a
warming cage until the initiation of that mouse’s next trial.
For each subsequent trial the mouse was released from a
different start arm into the maze and allowed to locate the
platform. Platform location remained constant throughout
testing. RAWM performance was recorded and scored
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using EthoVision XT 8.0 video tracking software (Noldus
Information Technology). Every arm entry for each animal
was recorded and reviewed to ensure that the mice did
not employ nonspatial/kinesthetic strategies (that is,
chaining) to solve the task. No chaining response (defined
as a mouse consecutively entering three (or more) adjacent
arms to solve the task) was observed for either genotype.
Novel object recognition
This task of recognition memory utilizes the fact that
animals will spend more time exploring a novel object
compared with an object that they are familiar with in
order to satisfy their innate curiosity/exploratory
instinct. The test apparatus consisted of an open field
box measuring 39.4 cm × 78.8 cm change confirmed. in
diameter, and all sessions were video-recorded. On day
1 the animal was allowed to explore the open field box
for a 15-minute time period. The following day the ani-
mals were each exposed to a 10-minute information ses-
sion (that is, the A/A session with identical objects
present). This information session was followed by a
1-hour delay during which the animals were returned to
their home cages. After the delay the animals performed
a 10-minute dissimilar stimuli session (A/B). The objects
were made of hard plastic and had previously been
counterbalanced to control for any object preference
bias. The total amount of time spent with each object
was recorded and scored using fully automated EthoVi-
sion XT 8.0 video tracking software (Noldus Informa-
tion Technology).
The time spent was operationally defined as occurring
when an animal directed its nose to the object at a dis-
tance <2.0 cm and/or by the animal touching the object
with its nose or mouth. Data are presented as the D2
discrimination index. The D2 index is a common mea-
sure of discrimination between novel and familiar
objects, and is considered one of the most reliable mea-
sures of discrimination because it corrects for total
exploratory activity of each animal [29]. The D2 index is
calculated for an A/B session by examining the differ-
ence in time spent exploring the novel and familiar
objects divided by the total exploration time for both
objects:
D2 = (novel − familiar)/(novel + familiar)
The D2 index thus corrects for total exploratory beha-
vior of each mouse.
Statistical analysis
All statistical analyses were performed using GraphPad
Prism Version 5.00 (GraphPad Software, San Diego,
CA¸USA). In the cross-sectional study design, experi-
mental groups consisted of two genotypes at four
different ages: 7 months, 11 months, 15 months, and
24 months. Each group used a ~50:50 ratio of males to
females. The number of mice used per group was 5 to 12
mice per group. Unless otherwise indicated, for WT mice
there were 10 aged 7 months, nine aged 11 months, five
aged 15 months, and 10 aged 24 months; and for KI mice,
there were nine aged 7 months, five aged 11 months, 10
aged 15 months, and five aged 24 months.
Comparison between individual experimental groups
was performed by unpaired t test where appropriate.
Regression analysis for RAWM and novel object recog-
nition (NOR) cognitive data was modeled via linear
regression in GraphPad with genotype, age, and errors/
D2 index as independent variables and using a 95% con-
fidence interval. Data are expressed as the mean ± the
standard error of the mean. Differences between means
from experimental groups were considered significant at
the P <0.05 level.
Results
Vestibulomotor behavior
The vestibulomotor behavior of APP/PS1 KI and WT
control mice is presented in Figure 1. As shown in
Figure 1A, no differences were observed between APP/
PS1 KI and WT mice in grip strength performance.
Further, the grip strength remained consistent across
the age groups for both APP/PS1 KI mice and their WT
counterparts.
No differences in beam walk performance were
observed between genotypes or for any age group of
mouse tested (Figure 1B). The number of foot slips for
both APP/PS1 KI and WT mice increased as the size of
the bar decreased. APP/PS1 KI mice made 1.92 ± 0.26
foot slips compared with 1.46 ± 0.37 foot slips for the
WT mice crossing the 3 cm beam. For the 2 cm beam,
the APP/PS1 KI mice made 9.69 ± 1.09 foot slips while
the WT mice made 8.36 ± 0.70 foot slips. Figure 1B
also shows the APP/PS1 KI and WT mice performance
on the 1 cm beam (APP/PS1 KI mice had 20.28 ± 1.54
foot slips compared with 17.92 ± 1.00 foot slips for WT
mice).
The open field behavioral task to assess ambulatory
movement showed no difference between APP/PS1 KI
and WT mice in distance traveled (Figure 1C) or in
movement speed (Figure 1D) for any age group. Simi-
larly, no differences in habituation behavior were
observed in the open field task for either genotype or
for any age group (data not shown).
Finally, no differences were observed at any age group
between APP/PS1 KI and WT mice in rotor rod perfor-
mance (Figure 1E), although the younger animals
(7 months old) performed this task somewhat better
than the older age groups. Interestingly, performance
was negatively correlated with the weight of the animals
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(Figure 1E, insert). Specifically, WT mice performance
showed a highly significant negative correlation with
weight (P = 0.004), and APP/PS1 KI mice showed a
similar pattern that did not reach statistical significance
(P = 0.052).
Anxiety-related behavior
The anxiety-related behavior of APP/PS1 KI and WT
mice was assessed by two behavioral tests: analysis of
time spent in the center zone versus peripheral zone of
the open field arena; and the elevated plus maze task.
As shown in Figure 2A, no differences were seen
between APP/PS1 KI and WT mice, or between any age
group of mice, in the amount of time each mouse spent
in the open center zone of the open field behavioral
task. Similarly, in the elevated plus maze task, both the
APP/PS1 KI and WT mice spent more time in the
enclosed arms compared with the open arms, and this
was consistent across all age groups (Figure 2B). No sig-
nificant differences were observed between APP/PS1 KI
and WT mice at any age.
Cognitive behavior
The cognitive behavior of APP/PS1 KI and WT mice
was tested in the RAWM and NOR behavioral tasks -
tests that measure spatial reference memory and recog-
nition memory, respectively.
In the RAWM, there was no difference in performance
between APP/PS1 KI mice and WT mice at 7 months of
age (Figure 3A). In contrast, APP/PS1 KI mice aged 11
months old (Figure 3B), 15 months old (Figure 3C), and
24 months old (Figure 3D) performed significantly worse
in the RAWM task than did the WT mice of the same
ages. When the RAWM maze data are analyzed as a func-
tion of errors made versus age of the animals (Figure 3E),
it is evident that APP/PS1 KI mice progressively increase
the number of errors they make as they age (and the dis-
ease progresses).
In the NOR behavior task, the APP/PS1 KI and WT
mice both showed a clear preference for novel object
exploration during the dissimilar stimuli (A/B) session
compared with the familiar at the ages of 7 and 11 months
old (Figure 3F). However, in the groups of 15 and
Figure 1 Motor behavior of APP/PS1 KI and wild-type control mice. (A) No differences in grip strength are observed between amyloid
precursor protein/presenilin-1 knock-in (APP/PS1 KI) mice and their wild-type (WT) counterparts in any age group. (B) No performance
differences are observed between APP/PS1 KI and WT mice for any age group in the beam walk task. (C), (D) Open field performance shows no
significant differences in ambulatory movement, as assessed by (C) distance traveled or(D) movement velocity, between APP/PS1 KI and WT
mice for any age group. (E) Rotor rod performance shows no differences between APP/PS1 KI and WT mice for any age group. However,
performance is negatively correlated with weight (E insert) for the WT animals (P = 0.004) and is almost significantly correlated for APP/PS1 KI
mice performance (P = 0.052). Number of mice: 10 WT and nine KI mice aged 7 months; five WT and eight KI mice aged 11 months; eight WT
and eight KI mice aged 15 months; and eight WT and five KI mice aged 24 months.
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24 month olds, the APP/PS1 KI mice lost the ability to
discriminate between familiar and novel objects and were
significantly impaired compared with the WT controls
(P = 0.044 for 15 month olds, P = 0.041 for 24 month
olds). Each animal tested had an exploration time >10 sec-
onds with each object, and no significant difference in
movement speed (velocity range: 2.4 to 3.6 cm/second)
was observed between genotypes or age groups. When the
NOR task data are analyzed as a function of the D2 recog-
nition index versus age of the animals (Figure 3G), it is
evident that APP/PS1 KI mice also become progressively
impaired in this task as they age and the AD-relevant
pathology progresses.
Discussion
Many lines of genetically altered mice have been generated
during the past few decades in an effort to better under-
stand the pathogenesis of AD. These mouse models of AD
pathobiology have provided significant neuropathological,
biochemical, physiological, and behavioral insights into
AD pathogenesis. Many of the AD mouse models differ in
the site of the mutation in APP, or in the number of APP
Figure 2 Anxiety-related behavior of APP/PS1 KI and wild-type control mice. (A) No difference in the time spent exploring in the center
zone between the amyloid precursor protein/presenilin-1 knock-in (APP/PS1 KI) mice and the wild-type (WT) mice was observed in any age
group. (B) Elevated plus maze anxiety behavior is also similar between APP/PS1 KI and WT mice for all ages. Number of mice: 10 WT and nine KI
mice aged 7 months; five WT and eight KI mice aged 11 months; eight WT and eight KI mice aged 15 months; and eight WT and five KI mice
aged 24 months.
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mutations in one mouse, or the addition of mutations in
PS1 or tau. In general, the genetic differences result in
each mouse model having a unique pathobiology that
makes it acutely useful for preclinical testing of a particu-
lar type of AD-relevant therapeutics. For example, if the
mechanism of action of a specific preclinical therapeutic is
to decrease cytokine overproduction, then a mouse model
that demonstrates cytokine overproduction is needed for
accurate testing of the therapeutic.
Improvements in behavioral endpoints are often the
gold standard used to demonstrate efficacy of preclinical
therapeutics. However, for such endpoints to be useful,
Figure 3 Cognitive behavior of APP/PS1 KI and wild-type control mice. Radial arm water maze (RAWM) performance for each age group:
(A) no observable difference is seen between amyloid precursor protein/presenilin-1 knock-in (APP/PS1 KI) mice and wild-type (WT) mice at
7 months of age; however, cognitive deficits are observed in the APP/PS1 KI mice at (B) 11 months, (C) 15 months, and (D) 24 months.
(E) RAWM performance as a function of total errors across the four age groups. The WT cognitive performance remained relatively constant
across the age groups, while APP/PS1 KI cognitive performance became more impaired as age increased. Data are plotted as mean (solid line)
and confidence intervals (dashed lines). (F) Novel object recognition (NOR) performance in APP/PS1 KI and WT mice. The D2 recognition index is
used to control for total exploration time: D2 = (novel - familiar)/(novel + familiar). Beginning at 15 months of age, the APP/PS1 KI mice show an
inability to discriminate between objects while the WT mice are still able to discriminate. (G) NOR performance as a function of D2 recognition
index across the four age groups. The WT cognitive performance remained relatively constant across the age groups, while APP/PS1 KI cognitive
performance became more impaired as age increased. N = 5 to 10 mice per group. *P <0.05, for APP/PS1 KI compared with WT. Number of
mice: 10 WT and nine KI mice aged 7 months; five WT and 12 KI mice aged 11 months; 10 WT and 10 KI mice aged 15 months; and seven WT
and five KI mice aged 24 months.
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it is necessary to know when cognitive deficits reprodu-
cibly develop in the AD mouse model in relation to
the particular druggable target of interest. As shown in
Figure 4, the temporal time courses can be quite differ-
ent between commonly used models. In addition, some
behavioral tasks are clearly more sensitive to cognitive
deficit detection at earlier ages. Figure 4 also shows how
noncognitive behaviors, such as increased activity in
motor tasks, should be considered in the selection of
the most appropriate preclinical model to use for a par-
ticular study, because these noncognitive behaviors may
interfere with the interpretation of cognitive tasks.
To assess the onset and progression of the cognitive
impairments in the APP/PS1 KI mouse model, we have
performed a comprehensive behavioral analysis across
the lifespan of this model from 7 to 24 months old. Our
data document clear age-dependent cognitive deficits in
the APP/PS1 KI mice in both recognition memory
(NOR) and spatial reference memory (RAWM) that
become more prominent with increasing age. Further, in
Figure 4 we compare the APP/PS1 KI mouse model
with other AD mouse models in regard to the onset/
progression of AD-relevant impairments in motor func-
tion, anxiety-related behavior, and cognition in an
attempt to clarify how the APP/PS1 KI model fits into
the growing literature on modeling AD in rodents. The
data presented here for motor function, anxiety-related
behavior, and cognitive deficits are critically important
to the future application and utility of this model in pre-
clinical testing of AD-relevant therapeutics by: establish-
ing baseline behavioral characteristics of this model; and
providing valuable information helpful in appropriate
study design. These are important observations, as they
establish baseline motor function and anxiety behavior,
which is important to know in any mouse model prior
to assessing cognitive functioning to avoid unwanted
confounds [30,31].
In contrast to a number of the mice strains shown in
Figure 4, which were found to have motor impairment
and hyperactivity, the APP/PS1 KI mice exhibit no differ-
ences in ambulatory movement, grip strength, or coordi-
nation when compared with WT controls at any of the
ages tested. There were also no anxiety-related behavior
deficits seen at any age in the APP/PS1 KI mice in the ele-
vated plus maze tasks. This is in contrast to the Tg2576,
J20, APP/PS1, and 5xFAD mice, which all were found to
have increased anxiety-related behavior in the elevated
plus maze task. In the open field task, animals with ele-
vated anxiety levels will spend little time exploring the
center of the chamber [30,32]. The APP/PS1 KI mice do
not exhibit anxiety-related behavior, as they showed nor-
mal exploration of the center of the open field chamber.
Anxiety behavior did not differ between APP/PS1 KI mice
and WT mice for any age tested. Our results therefore
demonstrate that there are no deficits in either motor
function or anxiety levels that could potentially confound
cognitive testing in this mouse model of AD, which is
dissimilar to the majority of the mouse models shown in
Figure 4.
Attempts to model AD-relevant cognitive deficits in
mouse models have met with some degree of success
[33,34]. Reference memory is a type of memory that is
often assessed in various mouse models of AD because
deficits in this type of memory are highly specific for
hippocampal function (one of the earliest/most severely
affected brain regions in human AD) [35]. One common
method for assessing deficits in hippocampal-based
reference memory is through the use of exploration-
based memory tasks such as the Morris water maze and
the RAWM [33]. Here we observe deficits in spatial
reference memory for the APP/PS1 KI mice when tested
in the RAWM. These deficits in spatial reference mem-
ory are first evident in the 11 month age group, and
continue to progress as the age/pathology increases in
this model. The temporal onset and progression of cog-
nitive impairment compared with other commonly used
AD mouse models can be seen in Figure 4. For example,
compared with other APP and PS1 AD mouse models,
such as the APP/PS1 model and the APP + PS1 model,
the onset of cognitive deficits in the APP/PS1 KI model
appears to occur slightly later in life. Both the APP +
PS1 model and the APP/PS1 model show deficits at 4 to
6 months of age [36-39], whereas the APP/PS1 KI mice
show deficits starting at 11 months old (Figure 3).
Another commonly tested type of AD-relevant mem-
ory is that of recognition memory. The most common
way to assess recognition memory in mice is through
the use of the NOR task [33]. Here we see cognitive
impairment in the NOR task manifest in the APP/PS1
KI model at 15 months of age. As shown in Figure 4,
this temporal pattern is similar to the onset of NOR def-
icits in some other AD mouse models, such as the
Tg2576 mice and the APP + PS1 model. In contrast,
some mouse models such as the PDAPP, APP23,
TgCRND8, J20, 5xFAD, and 3xTG-AD mice show
impairment in recognition memory at a younger age.
Overall, for many of the AD mouse models it appears
that deficits in spatial working memory (Morris water
maze and RAWM) become apparent earlier than deficits
in recognition memory (NOR).
With regard to b-amyloid, similar to other commonly
used models of AD such as the Tg2576 mouse and the
5xFAD mouse, in the APP/PS1 KI model the amyloid
burden occurs prior to the onset of cognitive deficits
[40-43]. Other potential therapeutic targets such as ele-
vated levels of oxidative stress and neuroinflammation
also occur before the observable cognitive deficits in the
APP/PS1 KI mouse model [12,14,17,44]. With respect to
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Figure 4 Comparison of behavior changes in APP/PS1 KI mice with other common Alzheimer’s disease mouse models. Data analysis
from the literature focused on a compilation of the most widely used behavioral tasks to assess the onset/progression of motor function
impairment, anxiety-related behavior, and cognitive impairment. Blue data, the Alzheimer’s disease (AD) mouse performed the same as the wild-
type (WT) control; yellow data, the AD mouse was increased from control; red data, the AD mouse was decreased from control. The numbers
within the data boxes refer to the literature citation. APP/PS1 KI, amyloid precursor protein/presenilin-1 knock-in.
Webster et al. Alzheimer’s Research & Therapy 2013, 5:28
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oxidative stress, the APP/PS1 KI mouse model is also
considerably different from other models such as the
Tg2576 and 3xTG-AD mice in the magnitude and tem-
poral time course of oxidative stress [15,44-48]. Elevated
levels of oxidative stress have been linked to the cogni-
tive deficits seen in AD [49,50]. In a study of the APP/
PS1 KI mice [18], NADPH oxidase (a marker of oxida-
tive stress) was reported to increase with the age of the
animal and correlate with increased b-amyloid levels.
Further, this same study reported that NADPH oxidase
is correlated with APP/PS1 KI behavioral performance in
the Stone T-maze, with lower levels of NADPH oxidase
and slight deficits observable at 4 to 6 months of age and
both becoming more pronounced by 16 to 19 months of
age [18]. This provides an example of how the APP/PS1
KI mouse could be a useful model to test preclinical thera-
peutics targeted at reducing oxidative stress.
AD is a very complex disease, with many interrelated
mechanisms and pathologies occurring concomitantly.
Although no animal model fully replicates the human
disease, AD mouse models are useful to investigate dif-
ferent aspects of AD pathology and disease progression.
AD mouse models have been invaluable in advancing
our understanding of disease mechanisms and in precli-
nical testing of potential therapeutics. Paramount to the
selection of the appropriate model for evaluation of
potential therapeutic interventions is demonstration that
the desired relevant target for the preclinical therapeutic
is present in the model at a therapeutically relevant
time. For example, the APP/PS1 KI model used here is
an ideal model for assessing the pathogenesis and effects
of early oxidative stress or dysregulated neuroinflamma-
tion as we recently showed [17]. In contrast, the APP/
PS1 KI model lacks AD-relevant tau pathology. This
model would therefore be inappropriate to examine
topics relating to the effect of microtubule-associated
tau disruption in AD. Instead, a model such as the
3xTG-AD mouse (or another relevant model showing
tau pathology) should be selected instead. Similarly, if
AD-related motor deficits [51] are the target of research
interest, selection of an appropriate model (Figure 4)
showing motor deficits such as the Tg2576 or 5xFAD
mouse would be salient, whereas a model like the APP/
PS1 KI model that does not develop motor deficits
would not be useful. Conversely, if AD-related cognitive
deficits are of interest, then motor deficits need to be
accounted for, or else a model that lacks motor deficits
but that displays cognitive impairment should be
selected so as to eliminate possible motor related con-
founds [31].
Each transgenic mouse model of AD provides different
insights into aspects of AD pathology and progression.
Careful forethought is therefore required in the selection
of an optimal model based on specific research interests.
Our hope is that, with regard to motor and cognitive defi-
cits relating to AD, the discussion and Figure 4 presented
here can help in the selection of the ideal model by pro-
viding an overview of the development and time course of
behavioral deficits in the commonly used mouse models
of AD.
Conclusion
This study is the first comprehensive behavioral analysis
reported for the APP/PS1 KI mouse model of AD and
the results presented here add to a growing literature
for this model. The lack of any motor/coordination defi-
cits or abnormal anxiety levels, coupled with an age/dis-
ease-related cognitive decline and the high physiological
relevance of this model, make it well suited for utiliza-
tion in preclinical testing of AD-relevant therapeutics.
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